Calyxt, Inc., a technology company, focuses on delivering plant-based solutions in the United States. It engages in the development of improved digestibility alfalfa; high fiber wheat; high oleic low linolenic soybeans; winter oats; hemp; fat soybeans; and cold storable potatoes. As of March 4, 2021, the company had nine projects at Phase I stage or later in development across alfalfa, hemp, oats, soybeans, and wheat. Calyxt, Inc. has a research collaboration with NRGene, which includes the adoption of NRGene's cloud-based genomics platform to support various research projects; and a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and various geographies outside the United States. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
IPO Year: 2017
Exchange: NASDAQ
Website: calyxt.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2022 | $6.00 → $4.00 | Buy | Canaccord Genuity |
| 11/2/2021 | $10.00 | Buy | ROTH Capital |
Canaccord Genuity reiterated coverage of Calyxt with a rating of Buy and set a new price target of $4.00 from $6.00 previously
ROTH Capital initiated coverage of Calyxt with a rating of Buy and set a new price target of $10.00
Canaccord Genuity resumed coverage of Calyxt with a rating of Buy and set a new price target of $16.00
Canaccord Genuity reiterated coverage of Calyxt with a rating of Buy and set a new price target of $16.00 from $8.00 previously
SC 13G/A - Cibus, Inc. (0001705843) (Subject)
SC 13G - Cibus, Inc. (0001705843) (Subject)
SC 13D - Cibus, Inc. (0001705843) (Subject)
SC 13D - Cibus, Inc. (0001705843) (Subject)
SC 13D - Cibus, Inc. (0001705843) (Subject)
SC 13D/A - Cibus, Inc. (0001705843) (Subject)
SC 13D/A - Calyxt, Inc. (0001705843) (Subject)
SC 13D/A - Calyxt, Inc. (0001705843) (Subject)
SC 13G/A - Calyxt, Inc. (0001705843) (Subject)
SC 13G/A - Calyxt, Inc. (0001705843) (Subject)
—Successfully produced squalene, an important ingredient for personal care products and vaccine adjuvants— —Continued to progress customer acquisition activities, including evaluating an incremental 37 customer chemistries for development using PlantSpring™ and BioFactory™ technologies— —Signed agreement with Evologic Technologies to further develop and scale production of its Plant Cell Matrix™ technology platform— —Continuing board-level evaluation of a full range of potential strategic alternatives to maximize shareholder value— —Selected for membership to BioMADE, a Department of Defense-sponsored initiative that brings together industrial, academic and non-profit entities to advance US
ROSEVILLE, Minn., Oct. 27, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, November 3, 2022, at 4:30 p.m. ET to discuss results for the third quarter ended September 30, 2022. A press release detailing these results will be issued prior to the call. President and Chief Executive Officer, Michael A. Carr, and Chief Financial Officer, Bill Koschak, will host the conference call. The conference call will be webcast and can be accessed via the investor relations section of the Company's
Evaluated nine new customer demand-driven plant-based chemistries in the quarter, bringing cumulative chemistries evaluated for development to 95, of these 31 meet Calyxt's target profile and several are the subject of term sheet discussions Engineering solution for a high-value molecule planned to be delivered in early 2023 to a large global consumer packaged goods company Progressing discussions with multiple potential infrastructure partners who would produce chemistries in various sizes of bioreactors from pilot to commercial scale Evaluating term sheets for technology licensing and for licensing of traits Management to host conference call and webcast today at 4:30 p.m. ET ROSEVILLE, Mi
ROSEVILLE, Minn., July 21, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time to discuss results for the second quarter ended June 30, 2022. A press release detailing these results will be issued prior to the call. President and Chief Executive Officer, Michael A. Carr, and Chief Financial Officer, Bill Koschak, will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company's website here. T
ROSEVILLE, Minn., April 21, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, May 5, 2022, at 4:30 p.m. Eastern Time to discuss results for the first quarter ended March 31, 2022. A press release detailing these results will be issued prior to the call. President and Chief Executive Officer, Michael A. Carr, and Chief Financial Officer, Bill Koschak, will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, whic
ROSEVILLE, Minn., March 3, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, today announced financial results for its fourth quarter and full year ended December 31, 2021. "Last year was transformational for Calyxt, as we evolved our strategic direction to focus our innovations on plant-based technology and production for new customers in an expanded group of end markets, becoming a synthetic biology company in our own right," said Michael A. Carr, President and Chief Executive Officer at Calyxt. "Since the start of the fourth quarter o
ROSEVILLE, Minn., Feb. 24, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, will hold a conference call on Thursday, March 3, 2022, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year ended December 31, 2021. A press release detailing these results will be issued prior to the call. President and Chief Executive Officer, Michael A. Carr, and Chief Financial Officer, Bill Koschak, will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a present
ROSEVILLE, Minn., Nov. 4, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, today announced financial results for its third quarter ended September 30, 2021. "Since I joined the Company as CEO in July, Calyxt has made significant progress, aligning on a new strategic direction that leverages our Company's strengths and key areas of differentiation, and positions Calyxt as a synthetic biology company in its own right," said Michael A Carr, President and Chief Executive Officer at Calyxt. "The cornerstone of our strategy is to leverage our proprietary PlantSpring technology platform with our BioFactory production system, which together enable us to
ROSEVILLE, Minn., Oct. 19, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) will hold a conference call on Thursday, November 4, 2021, at 4:30 p.m. Eastern time to discuss its results for the third quarter ended on September 30, 2021. A press release detailing these results will be issued prior to the call. Chief Executive Officer Michael A. Carr and Chief Financial Officer Bill Koschak will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company's website here. To access the call, please use the following information: Dat
ROSEVILLE, Minn., Aug. 5, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, today announced financial results for its second quarter ended June 30, 2021. "We made significant progress in the second quarter, notably appointing Michael A. Carr as President and Chief Executive Officer where he will lead us in our efforts to advance the evolution of our plant-based technology platform," said Yves Ribeill, Ph.D., Executive Chair. "Our scientific and technical teams have made important advances across our hemp breeding technologies. In addition to s
4 - Cibus, Inc. (0001705843) (Issuer)
4 - Cibus, Inc. (0001705843) (Issuer)
3 - Cibus, Inc. (0001705843) (Issuer)
4/A - Cibus, Inc. (0001705843) (Issuer)
4 - Cibus, Inc. (0001705843) (Issuer)
3 - Cibus, Inc. (0001705843) (Issuer)
4/A - Cibus, Inc. (0001705843) (Issuer)
4 - Cibus, Inc. (0001705843) (Issuer)
4 - Cibus, Inc. (0001705843) (Issuer)
4 - Cibus, Inc. (0001705843) (Issuer)
EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said
-- Calyxt Announces 1-for-5 Reverse Stock Split of Common Stock -- ROSEVILLE, Minn., May 19, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt" or the "Company") today announced the results of the special meeting of its stockholders held on May 18, 2023. At the special meeting, Calyxt's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Class A common stock and Class B common stock to the equity holders of Cibus Global, LLC ("Cibus") as part of the previously announced proposed merger with Cibus. The closing of the merger is anticipated to take place on or around Wednesday, May 31, 2023, subject to the satisfaction of the remainin
—Proposed merger with Cibus Global Expected to Close in Q2 2023— —1-for-10 reverse stock split executed— —Current customer projects under development are on track— —Evologic Technologies completed initial phase of project to scale production of Calyxt's Plant Cell Matrix™ and BioFactoryTM technologies— ROSEVILLE, Minn., May 1, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023. Merger Agreement with Cibus On January 17, 2023, Calyxt announced it had entered into a definitive merger agreement (the Merger Agreement) with Cibus Global, LLC (Cibus), a leader in precis
ROSEVILLE, Minn., April 24, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt" or the "Company") today announced that it has completed the previously announced reverse stock split of Calyxt's common stock, par value $0.0001 per share ("Common Stock"), at a ratio of 1-for-10. The reverse stock split was previously approved by the Company's stockholders at the annual meeting of shareholders on June 1, 2022. Calyxt filed an amendment to its amended and restated certificate of incorporation to effectuate the reverse stock split as of 4:30 p.m. Eastern time on April 24, 2023 (the "effective date") and the Common Stock will begin trading on an adjusted basis giving effect to the reverse sto
ROSEVILLE, Minn. and SAN DIEGO, April 18, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that the registration statement on Form S-4, initially filed with the U.S. Securities and Exchange Commission ("SEC") by Calyxt on February 14, 2023, and amended on April 14, 2023 (as amended, the "Registration Statement"), has been declared effective by the SEC. The Registration Statement was filed in connection with the previously announced merger of Calyxt and Cibus a
ROSEVILLE, Minn., April 7, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt" or the "Company") today announced that it will proceed with the 1-for-10 reverse stock split previously approved by the Company's shareholders at the annual meeting of shareholders on June 1, 2022. Calyxt plans to file an amendment to its certificate of incorporation to effectuate the reverse stock split after the close of trading on April 24, 2023, and Calyxt's common stock, par value $0.0001 per share, will begin trading on an adjusted basis giving effect to the reverse stock split on April 25, 2023. When the reverse stock split is effective, every ten shares of the Company's common stock issued and outst
NEW YORK, March 06, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company for which Cellectis owns 49.1% (as of December 31, 2022) of its issued and outstanding common stock, today announced operating and financial results for its fourth quarter ended December 31, 2022. The contents of Calyxt's announcement are included below: —Announced proposed merger with Cibus Global and filed initial registration statement on Form S-4— —Current customer projects under development are
—Announced proposed merger with Cibus Global and filed initial registration statement on Form S-4— —Current customer projects under development are on track— —Signed agreement with Evologic Technologies to further develop and scale production of its Plant Cell Matrix™ and BioFactoryTM technologies— ROSEVILLE, Minn., March 2, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, today announced operating and financial results for its fourth quarter ended December 31, 2022. Merger Agreement with Cibus On January 17, 2023, Calyxt announced it had entered into a definitive merger agreement with Cibus Global, LLC (Cibus), a leader in precision gene editing in
ROSEVILLE, Minn. and SAN DIEGO, Feb. 15, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that Calyxt has filed a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") on February 14, 2023. The combined company is expected to be renamed Cibus, Inc. and remain listed on the Nasdaq Capital Market under the proposed ticker symbol CBUS. The Registration Statement contains a preliminary proxy statement / prospectus in connection with the previously announced merger of Calyxt and Cibus. Although the Registration
NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and gene therapies, announced today that Cibus Global LLC, a Delaware limited liability company ("Cibus"), and Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt"), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the "Merger Agreement"), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. T
EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said
ROSEVILLE, Minn., Oct. 12, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, today announced the appointment of Seth Dobrin, Ph.D., to the Company's Scientific Advisory Board (SAB). Dr. Dobrin is the Global Chief Artificial Intelligence (AI) Officer at IBM and brings extensive leadership experience and a track record of transforming companies through data and AI. "We warmly welcome Seth to our Scientific Advisory Board. Seth is a visionary whose deep experience bringing AI-based business solutions to major global corporations will be invaluable as we continue to develop and augment the AI and machine learning (AIML) capabilities of our PlantSprin
ROSEVILLE, Minn., July 15, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based biotechnology platform company, today announced the appointment of Michael A. Carr as President and Chief Executive Officer, effective July 27, 2021. Mr. Carr will also serve as a member of Calyxt's Board of Directors. Mr. Carr was most recently the Vice President of M&A, Strategy, and Innovation at Darling Ingredients, Inc., a global developer and producer of sustainable natural ingredients and renewable energy. "Michael's operational, financial, and investment experience, paired with his diverse knowledge across industries including health, nutrients, bioenergy and services will be integral as we adva
8-K - Cibus, Inc. (0001705843) (Filer)
8-K - Cibus, Inc. (0001705843) (Filer)
424B5 - Cibus, Inc. (0001705843) (Filer)
8-K - Cibus, Inc. (0001705843) (Filer)
8-K - Cibus, Inc. (0001705843) (Filer)
424B5 - Cibus, Inc. (0001705843) (Filer)
8-K - Cibus, Inc. (0001705843) (Filer)
424B5 - Cibus, Inc. (0001705843) (Filer)
8-K - Cibus, Inc. (0001705843) (Filer)
10-Q - Cibus, Inc. (0001705843) (Filer)